Vadadustat

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 110 publications

A Near-Infrared Photoactivatable, Brain-Penetrant Prodrug of the Prolyl Hydroxylase Inhibitor Vadadustat for Neuroprotection in Ischemic Stroke.

A Near-Infrared Photoactivatable, Brain-Penetrant Prodrug of the Prolyl Hydroxylase Inhibitor Vadadustat for Neuroprotection in Ischemic Stroke.

Journal: Journal of medicinal chemistry

Published: May 02, 2026

Comparing Vadadustat and Darbepoetin in Maintenance Dialysis with CKD-Related Anemia: A Win Statistics Analysis.

Comparing Vadadustat and Darbepoetin in Maintenance Dialysis with CKD-Related Anemia: A Win Statistics Analysis.

Journal: Journal of the American Society of Nephrology : JASN

Published: March 17, 2026

Supramolecular host-guest interactions of TRYVIO and VAFSEO with a benzotriazole nanocapsule: A density functional theory study.

Supramolecular host-guest interactions of TRYVIO and VAFSEO with a benzotriazole nanocapsule: A density functional theory study.

Journal: Journal of molecular graphics & modelling

Published: March 16, 2026

Efficacy and safety of prolyl hydroxylase inhibitors for anemia in chronic kidney disease: a network meta-analysis.

Efficacy and safety of prolyl hydroxylase inhibitors for anemia in chronic kidney disease: a network meta-analysis.

Journal: Renal failure

Published: February 03, 2026

Barriers and Facilitators to Vadadustat Use for Managing Anemia in Adult Patients Undergoing Dialysis: A Qualitative Evidence Synthesis.

Barriers and Facilitators to Vadadustat Use for Managing Anemia in Adult Patients Undergoing Dialysis: A Qualitative Evidence Synthesis.

Journal: Cureus

Published: January 07, 2026

Impact of SLCO1B1 Gene Polymorphisms on Vadadustat Pharmacokinetics.

Impact of SLCO1B1 Gene Polymorphisms on Vadadustat Pharmacokinetics.

Journal: European journal of drug metabolism and pharmacokinetics

Published: January 02, 2026

Discovery of 3-(Arylamido)pyrazolopyridine HIF-2α Agonists and a Codrug Strategy with Prolyl Hydroxylase Inhibition for Synergistic Treatment of Renal Anemia.

Discovery of 3-(Arylamido)pyrazolopyridine HIF-2α Agonists and a Codrug Strategy with Prolyl Hydroxylase Inhibition for Synergistic Treatment of Renal Anemia.

Journal: Journal of medicinal chemistry

Published: November 21, 2025

Erythropoiesis-Stimulating Agents (ESAs) in Chronic Kidney Disease and Cancer-Related Anemia: A Narrative Review of Literature.

Erythropoiesis-Stimulating Agents (ESAs) in Chronic Kidney Disease and Cancer-Related Anemia: A Narrative Review of Literature.

Journal: Cureus

Published: September 29, 2025

Understanding Pharmacokinetic-Drug Interactions With Drugs Approved by the US Food and Drug Administration in 2024 to Better Manage the Risk of Drug Interactions With Concomitant Medications: A Review of Clinical Data From New Drug Applications.

Understanding Pharmacokinetic-Drug Interactions With Drugs Approved by the US Food and Drug Administration in 2024 to Better Manage the Risk of Drug Interactions With Concomitant Medications: A Review of Clinical Data From New Drug Applications.

Journal: Current therapeutic research, clinical and experimental

Published: August 07, 2025

Light-driven biosensor for the rapid and selective detection of hypoxia-inducible factor-prolyl hydroxylase domain inhibitors in aqueous media and saliva.

Light-driven biosensor for the rapid and selective detection of hypoxia-inducible factor-prolyl hydroxylase domain inhibitors in aqueous media and saliva.

Journal: Mikrochimica acta

Published: July 21, 2025

Safety and Efficacy of Vadadustat Versus Darbepoetin Alfa for Chronic Kidney Disease-Related Anemia in Patients Receiving Dialysis by Baseline Erythropoiesis-Stimulating Agent Dose.

Safety and Efficacy of Vadadustat Versus Darbepoetin Alfa for Chronic Kidney Disease-Related Anemia in Patients Receiving Dialysis by Baseline Erythropoiesis-Stimulating Agent Dose.

Journal: Hemodialysis international. International Symposium on Home Hemodialysis

Published: July 11, 2025

QSPR analysis of the drugs used to treat renal failure and its complications using degree and modified reverse degree indices.

QSPR analysis of the drugs used to treat renal failure and its complications using degree and modified reverse degree indices.

Journal: Scientific reports

Published: June 25, 2025

Showing 1-12 of 110

Last Updated: 09/26/2026